Chronic Bronchitis News and Research

RSS

Second-hand smoke triggers complex inflammatory response

Second-hand smoke is associated with a number of diseases and conditions, including cancer, heart disease, and emphysema. It is an irritant to lung tissue and blood vessels, but the processes through which the body reacts to second-hand smoke comprise a mystery scientists are only beginning to unravel. Researchers at the University of Colorado-Denver are currently studying how second-hand smoke affects the lungs of rats, and so far it appears that second-hand smoke triggers a complex inflammatory response.

27 Aug 2010

Tips for management of COPD

What is the fourth leading cause of death in the United States? Many would be surprised to learn that chronic obstructive pulmonary disease (COPD) is, and the number of people with COPD is increasing. According to the COPD Foundation, more than 12 million Americans are currently diagnosed with COPD and an additional 12 million may not realize their shortness of breath and coughing are in fact symptoms of this debilitating condition.

20 Aug 2010

Forest Laboratories reports first-quarter diluted EPS of $0.39

Forest Laboratories, Inc., an international pharmaceutical manufacturer and marketer, announced that diluted earnings per share equaled $0.39 in the first quarter of fiscal 2011. Excluding the charge related to the United States Department of Justice investigations described below, and a charge of $50.0 million, or $0.17 per share net of tax, for a new product licensing fee, non-GAAP earnings per share for the first fiscal quarter were $0.95 per share.

20 Jul 2010

Chronic insomnia increases mortality risk

Individuals with chronic insomnia have an elevated risk of death, according to a research abstract that will be presented Monday, June 7, 2010, in San Antonio, Texas, at SLEEP 2010, the 24th annual meeting of the Associated Professional Sleep Societies LLC.

7 Jun 2010

Beta-blocker medications provide new hope for patients with COPD: Study

Patients with chronic obstructive pulmonary disease may have fewer respiratory flare-ups and longer survival if they take beta-blocker medications, according to a report in the May 24 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

25 May 2010

FDA issues complete response letter for roflumilast NDA

Forest Laboratories, Inc. and Nycomed today announced that the U.S. Food and Drug Administration (FDA) issued a complete response letter regarding the New Drug Application (NDA) for roflumilast. Roflumilast was reviewed as a potential treatment to reduce COPD exacerbations associated with chronic bronchitis in patients at risk for exacerbations.

18 May 2010

Forest, Nycomed to present data from six roflumilast posters at ATS International Conference

Forest Laboratories, Inc. and Nycomed today announced that they will present data from six roflumilast posters during the American Thoracic Society (ATS) International Conference being held in New Orleans, LA, May 14 through May 19, 2010. Roflumilast is an investigational anti-inflammatory, oral medication for the treatment of Chronic Obstructive Pulmonary Disease (COPD) associated with chronic bronchitis in patients at risk of exacerbations.

10 May 2010

Natural plant extract could help treat COPD and inflammatory disorders

A widely and safely used plant extract acts as a novel anti-inflammatory agent that may one day be used for the treatment of chronic obstructive pulmonary disease, or COPD, as well as other inflammatory conditions.

4 May 2010

70% of COPD patients under-diagnosed due to lack of disease knowledge

"It is high time to demystify COPD in order to better explain the issues and help people who suffer from this disease," says Dr. Jean Bourbeau, Director of the Respiratory, Epidemiology and Clinical Research Unit at the Montreal Chest Institute of the MUHC, and lead investigator of CanCOLD along with Dr. Wan Tan of The James Hogg iCAPTURE Centre for Cardiovascular and Pulmonary Research, University of British Columbia.

17 Apr 2010

Volcanic ash falls across Europe

Flights were cancelled across Europe today thanks to volcanic ash drifting in to northern Europe from Iceland. More than 250 flights were grounded from London’s Gatwick and Heathrow airports alone, leaving thousands of passengers stranded. The ash is drifting in from a volcanic eruption in Iceland and the cloud is capable of damaging jet engines that travel through it.

16 Apr 2010

Pernix Therapeutics Holdings acquires oral third-generation cephalosporin, CEDAX

Pernix Therapeutics Holdings, Inc. today announced the acquisition of the antibiotic CEDAX® (ceftibuten) from Shionogi Pharma, Inc.

25 Mar 2010

China Sky One Medical prepares for commercial launch 13 new SFDA approved products

China Sky One Medical, Inc., a leading fully integrated pharmaceutical company producing over-the-counter drugs in the People's Republic of China, today announced the pending commercial launch of 13 new SFDA approved products over the next few quarters.

22 Mar 2010

Almost 62% of Canadians age 65 and older use five or more classes of prescription drugs: CIHI study

Almost two-thirds (62%) of Canadians age 65 and older living in the community in six provinces are using five or more classes of prescription drugs, according to a study released today by the Canadian Institute for Health Information.

19 Mar 2010

Patients with COPD could benefit from treatment with drugs that block sestrin function

Chronic obstructive pulmonary disease (COPD) is defined by emphysema and/or chronic bronchitis. It destroys the normal architecture of the lung and inhibits the mechanical aspects of breathing, which prevents necessary gas exchange. Patients suffer from coughing fits, wheezing, and increased incidence of lung infections.

27 Jan 2010

Elevation Pharmaceuticals closes $30M tranched Series A financing

Elevation Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of new aerosol therapies for patients with respiratory diseases, announced today the closing of a $30 million tranched Series A financing.

21 Jan 2010

Moxifloxacin more favorable than amoxicillin/clavulanate for COPD exacerbations

Chronic obstructive pulmonary disease (COPD) affects a large number of subjects worldwide and is characterised by a progressively rising epidemiological, clinical and socio-economic impact. The objectives of treatment are to decrease the burden of the disease through relief of symptoms, improvement of exercise tolerance, and prevention and treatment of exacerbations.

21 Jan 2010

One-legged cycling can improve overall fitness in COPD patients

People with chronic-obstructive pulmonary disease (COPD) often find themselves in a downward spiral when it comes to their health. COPD, which includes chronic bronchitis and emphysema, means that the elasticity of the lungs is destroyed.

21 Jan 2010

FDA: Data from Spiriva HandiHaler do not support increased risks for stroke, heart attack or death

The U.S. Food and Drug Administration today announced that data from a recent review of the Spiriva HandiHaler, a long-acting respiratory treatment for chronic obstructive pulmonary disease (COPD), do not support an increased risk of stroke, heart attack, or death in patients using the medicine.

18 Jan 2010

Dendritic cell changes suggest new strategy to identify and treat debilitating lung disease

A new study links chronic obstructive pulmonary disease, or COPD, with increased activity of cells that act as sentinels to activate the body's immune system.

15 Dec 2009

Scientists explore various imaging techniques to gain new insight into lung disease

Chronic obstructive pulmonary disease (COPD), a respiratory disease commonly known as chronic bronchitis or emphysema, is the fourth leading cause of death worldwide. 600 million people live with COPD and while researchers have yet to find any real treatment or cure, Grace Parraga of Robarts Research Institute at The University of Western Ontario in London, Canada, is using various imaging techniques to gain new insight into the disease.

21 Nov 2009

Chronic Bronchitis News and Research

Second-hand smoke triggers complex inflammatory response

Tips for management of COPD

Forest Laboratories reports first-quarter diluted EPS of $0.39

Chronic insomnia increases mortality risk

Beta-blocker medications provide new hope for patients with COPD: Study

FDA issues complete response letter for roflumilast NDA

Forest, Nycomed to present data from six roflumilast posters at ATS International Conference

Natural plant extract could help treat COPD and inflammatory disorders

70% of COPD patients under-diagnosed due to lack of disease knowledge

Volcanic ash falls across Europe

Pernix Therapeutics Holdings acquires oral third-generation cephalosporin, CEDAX

China Sky One Medical prepares for commercial launch 13 new SFDA approved products

Almost 62% of Canadians age 65 and older use five or more classes of prescription drugs: CIHI study

Patients with COPD could benefit from treatment with drugs that block sestrin function

Elevation Pharmaceuticals closes $30M tranched Series A financing

Moxifloxacin more favorable than amoxicillin/clavulanate for COPD exacerbations

One-legged cycling can improve overall fitness in COPD patients

FDA: Data from Spiriva HandiHaler do not support increased risks for stroke, heart attack or death

Dendritic cell changes suggest new strategy to identify and treat debilitating lung disease

Scientists explore various imaging techniques to gain new insight into lung disease

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News